FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
William Blair analyst Tim Lugo reiterated a Market Perform rating on Sage Therapeutics (NASDAQ: SAGE).
The analyst comments "We rate shares of Sage Market Perform. We view Zurzuvaes PPD approval with a challenging label and the MDD CRL as a double... More
JPMorgan analyst Anupam Rama reiterated an Overweight rating and $29.00 price target on Sage Therapeutics (NASDAQ: SAGE)
The analyst comments "Earlier today, Sage announced that dalzanemdor (SAGE-718) did not show statistical difference on the primary endpoint of WAIS-IV in the PRECEDENT study... More
RBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $26.00 price target on Sage Therapeutics (NASDAQ: SAGE).
The analyst comments "This morning, SAGE provided topline data from the ph.II PRECEDENT trial of dalzanemdor in PD pts with MCI, the first of a series of studies in AD, PD, and HD set to read-out this year. We had been cautious into these initial results given non-definitive prior data, though believe the upside opportunity upon success had created some Street intrigue in the potential optionality dalzanemdor could provide. The PRECEDENT trial did... More
Mizuho analyst Vamil Divan reiterated a Neutral rating and $20.00 price target on Sage Therapeutics (NASDAQ: SAGE)
The analyst comments "This morning, Sage reported negative top-line data (see slides) from the Phase 2 PRECEDENT of dalzanemdor (its wholly-owned oral NMDA PAM previously known as... More
Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $28.00 price target on Sage Therapeutics (NASDAQ: SAGE).
The analyst comments "SAGE announced topline data from the Ph2 PRECEDENT study evaluating dalzanemdor (SAGE-718; NMDA receptor PAM; not in our model) in mild cognitive impairment (MCI) in Parkinson's Disease (PD), disclosing that the study did not meet its primary endpoint of change from baseline vs placebo on the Wechsler Adult Intelligence... More
Truist Securities analyst Joon Lee reiterated a Hold rating and $22.00 price target on Sage Therapeutics (NASDAQ: SAGE)
The analyst comments "This AM, SAGE announced failure of dalzanemdor for Parkinson's disease in the Ph2 PRECEDENT study. Drug demonstrated no signs of separation from pbo on WAIS-IV Coding Test... More
Raymond James analyst Danielle Brill reiterated a Market Perform rating on Sage Therapeutics (NASDAQ: SAGE).
The analyst comments "This morning, Sage presented topline Ph 2 data of SAGE-718 in Parkinsons Disease (PD; PRECEDENT), which failed to show any difference on the primary learning/memory performance endpoint vs. placebo (pbo; both arms +2 points vs... More
